The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Martina Bocchetta; Samantha Galluzzi; Patrick Gavin Kehoe; Eduardo Aguera; Roberto Bernabei; Roger Bullock; Mathieu Ceccaldi; Jean-Francois Dartigues; Alexandre de Mendonca; Mira Didic; Maria Eriksdotter; Olivier Felician; Lutz Froelich; Hermann-Josef Gertz; Merja Hallikainen; Steen G. Hasselbalch; Lucrezia Hausner; Isabell Heuser; Frank Jessen; Roy W. Jones; Alexander Kurz; Brian Lawlor; Alberto Lleo; Pablo Martinez-Lage; Patrizia Mecocci; Shima Mehrabian; Andreas Monsch; Flavio Nobili; Agneta Nordberg; Marcel Olde Rikkert; Jean-Marc Orgogozo; Florence Pasquier; Oliver Peters; Eric Salmon; Carmen Sanchez-Castellano; Isabel Santana; Marie Sarazin; Latchezar Traykov; Magda Tsolaki; Pieter Jelle Visser; Asa K. Wallin; Gordon Wilcock; David Wilkinson; Henrike Wolf; Goersev Yener; Dina Zekry; Giovanni B. Frisoni

doi:10.1016/j.jalz.2014.06.006

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

Martina Bocchetta, Samantha Galluzzi, Patrick Gavin Kehoe, Eduardo Aguera, Roberto Bernabei, Roger Bullock, Mathieu Ceccaldi, Jean-Francois Dartigues, Alexandre de Mendonca, Mira Didic, Maria Eriksdotter, Olivier Felician, Lutz Froelich, Hermann-Josef Gertz, Merja Hallikainen, Steen G. Hasselbalch, Lucrezia Hausner, Isabell Heuser, Frank Jessen, Roy W. JonesAlexander Kurz, Brian Lawlor, Alberto Lleo, Pablo Martinez-Lage, Patrizia Mecocci, Shima Mehrabian, Andreas Monsch, Flavio Nobili, Agneta Nordberg, Marcel Olde Rikkert, Jean-Marc Orgogozo, Florence Pasquier, Oliver Peters, Eric Salmon, Carmen Sanchez-Castellano, Isabel Santana, Marie Sarazin, Latchezar Traykov, Magda Tsolaki, Pieter Jelle Visser, Asa K. Wallin, Gordon Wilcock, David Wilkinson, Henrike Wolf, Goersev Yener, Dina Zekry, Giovanni B. Frisoni^*

^*Corresponding author for this work

MHeNs - Cognitive Neuropsychiatry and Clinical Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

e investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy-nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

Original language	English
Pages (from-to)	195-206
Journal	Alzheimer's & Dementia
Volume	11
Issue number	2
DOIs	https://doi.org/10.1016/j.jalz.2014.06.006
Publication status	Published - Feb 2015

Keywords

Biomarkers
Alzheimer's disease
Mild cognitive impairment
Diagnosis

Access to Document

10.1016/j.jalz.2014.06.006

Cite this

Bocchetta, M., Galluzzi, S., Kehoe, P. G., Aguera, E., Bernabei, R., Bullock, R., Ceccaldi, M., Dartigues, J.-F., de Mendonca, A., Didic, M., Eriksdotter, M., Felician, O., Froelich, L., Gertz, H.-J., Hallikainen, M., Hasselbalch, S. G., Hausner, L., Heuser, I., Jessen, F., ... Frisoni, G. B. (2015). The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's & Dementia, 11(2), 195-206. https://doi.org/10.1016/j.jalz.2014.06.006

@article{caa620c75f1644acb7d7f371098479c1,

title = "The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey",

abstract = "e investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy-nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.",

keywords = "Biomarkers, Alzheimer's disease, Mild cognitive impairment, Diagnosis",

author = "Martina Bocchetta and Samantha Galluzzi and Kehoe, {Patrick Gavin} and Eduardo Aguera and Roberto Bernabei and Roger Bullock and Mathieu Ceccaldi and Jean-Francois Dartigues and {de Mendonca}, Alexandre and Mira Didic and Maria Eriksdotter and Olivier Felician and Lutz Froelich and Hermann-Josef Gertz and Merja Hallikainen and Hasselbalch, {Steen G.} and Lucrezia Hausner and Isabell Heuser and Frank Jessen and Jones, {Roy W.} and Alexander Kurz and Brian Lawlor and Alberto Lleo and Pablo Martinez-Lage and Patrizia Mecocci and Shima Mehrabian and Andreas Monsch and Flavio Nobili and Agneta Nordberg and Rikkert, {Marcel Olde} and Jean-Marc Orgogozo and Florence Pasquier and Oliver Peters and Eric Salmon and Carmen Sanchez-Castellano and Isabel Santana and Marie Sarazin and Latchezar Traykov and Magda Tsolaki and Visser, {Pieter Jelle} and Wallin, {Asa K.} and Gordon Wilcock and David Wilkinson and Henrike Wolf and Goersev Yener and Dina Zekry and Frisoni, {Giovanni B.}",

year = "2015",

month = feb,

doi = "10.1016/j.jalz.2014.06.006",

language = "English",

volume = "11",

pages = "195--206",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier Science",

number = "2",

}

Bocchetta, M, Galluzzi, S, Kehoe, PG, Aguera, E, Bernabei, R, Bullock, R, Ceccaldi, M, Dartigues, J-F, de Mendonca, A, Didic, M, Eriksdotter, M, Felician, O, Froelich, L, Gertz, H-J, Hallikainen, M, Hasselbalch, SG, Hausner, L, Heuser, I, Jessen, F, Jones, RW, Kurz, A, Lawlor, B, Lleo, A, Martinez-Lage, P, Mecocci, P, Mehrabian, S, Monsch, A, Nobili, F, Nordberg, A, Rikkert, MO, Orgogozo, J-M, Pasquier, F, Peters, O, Salmon, E, Sanchez-Castellano, C, Santana, I, Sarazin, M, Traykov, L, Tsolaki, M, Visser, PJ, Wallin, AK, Wilcock, G, Wilkinson, D, Wolf, H, Yener, G, Zekry, D & Frisoni, GB 2015, 'The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey', Alzheimer's & Dementia, vol. 11, no. 2, pp. 195-206. https://doi.org/10.1016/j.jalz.2014.06.006

TY - JOUR

T1 - The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

AU - Bocchetta, Martina

AU - Galluzzi, Samantha

AU - Kehoe, Patrick Gavin

AU - Aguera, Eduardo

AU - Bernabei, Roberto

AU - Bullock, Roger

AU - Ceccaldi, Mathieu

AU - Dartigues, Jean-Francois

AU - de Mendonca, Alexandre

AU - Didic, Mira

AU - Eriksdotter, Maria

AU - Felician, Olivier

AU - Froelich, Lutz

AU - Gertz, Hermann-Josef

AU - Hallikainen, Merja

AU - Hasselbalch, Steen G.

AU - Hausner, Lucrezia

AU - Heuser, Isabell

AU - Jessen, Frank

AU - Jones, Roy W.

AU - Kurz, Alexander

AU - Lawlor, Brian

AU - Lleo, Alberto

AU - Martinez-Lage, Pablo

AU - Mecocci, Patrizia

AU - Mehrabian, Shima

AU - Monsch, Andreas

AU - Nobili, Flavio

AU - Nordberg, Agneta

AU - Rikkert, Marcel Olde

AU - Orgogozo, Jean-Marc

AU - Pasquier, Florence

AU - Peters, Oliver

AU - Salmon, Eric

AU - Sanchez-Castellano, Carmen

AU - Santana, Isabel

AU - Sarazin, Marie

AU - Traykov, Latchezar

AU - Tsolaki, Magda

AU - Visser, Pieter Jelle

AU - Wallin, Asa K.

AU - Wilcock, Gordon

AU - Wilkinson, David

AU - Wolf, Henrike

AU - Yener, Goersev

AU - Zekry, Dina

AU - Frisoni, Giovanni B.

PY - 2015/2

Y1 - 2015/2

N2 - e investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy-nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

AB - e investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it “always/frequently”) followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as “moderate”. Seventy-nine percent of responders felt “very/extremely” comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

KW - Biomarkers

KW - Alzheimer's disease

KW - Mild cognitive impairment

KW - Diagnosis

U2 - 10.1016/j.jalz.2014.06.006

DO - 10.1016/j.jalz.2014.06.006

M3 - Article

C2 - 25150733

SN - 1552-5260

VL - 11

SP - 195

EP - 206

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 2

ER -